前列腺癌异质性系统综述:解读多灶性疾病的克隆起源
该系统综述筛选PubMed 2009至2020年间1313篇摘要,最终纳入35项研究进行定性分析,评估前列腺癌瘤内异质性与克隆演化。原发灶研究(16项,4793例标本)对单克隆或多克隆起源缺乏共识,无一致驱动突变;转移灶研究(19项,732例标本)一致发现转移灶与潜在克隆的克隆关系及一致的躯干基因组畸变,提示单克隆转移祖细胞。
要点
- 原发灶单克隆或多克隆起源尚无共识,缺乏一致驱动突变。
- 转移灶与潜在克隆的克隆关系一致,提示单克隆转移祖细胞。
- 克隆动态与临床结局关系待研究,或为寡转移原发灶根治提供依据。
核心结论
- 原发灶克隆起源尚无共识且无一致突变,转移灶则一致提示单克隆转移祖细胞。
研究设计与样本
- 系统综述筛选PubMed 2009至2020年1313篇摘要,全文复习84篇,排除49篇,最终35项研究纳入定性分析。
主要发现
- 原发疾病研究共16项、4793例标本,对单克隆或多克隆起源缺乏共识,无一致突变导致原发前列腺癌。
- 转移灶与潜在克隆的克隆关系被一致识别,共19项研究、732例标本。
- 转移标本显示一致的躯干基因组畸变,提示单克隆转移祖细胞。
临床怎么用
- 克隆动态与临床结局关系需进一步研究,可能为寡转移前列腺癌原发灶根治是否获益提供生物学依据。
- 未来单细胞分辨率突变负荷研究有望识别致死性前列腺癌起源的克隆模式。
局限性
- 原发前列腺癌详细克隆分析受当前技术限制。
- 原发灶单克隆或多克隆起源缺乏共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Studies characterising genomic changes in prostate cancer (PCa) during natural progression have greatly increased our understanding of the disease. A better understanding of the evolutionary history of PCa would allow advances in diagnostics, prognostication, and novel therapies that together will improve patient outcomes. OBJECTIVE: To review the molecular heterogeneity of PCa and assess recent efforts to profile intratumoural heterogeneity and clonal evolution. EVIDENCE ACQUISITION: We screened a total of 1313 abstracts from PubMed published between 2009 and 2020, of which we reviewed 84 full-text articles. We excluded 49, resulting in 35 studies for qualitative analysis. EVIDENCE SYNTHESIS: In studies of primary disease (16 studies, 4793 specimens), there is a lack of consensus regarding the monoclonal or polyclonal origin of primary PCa. There is no consistent mutation giving rise to primary PCa. Detailed clonal analysis of primary PCa has been limited by current techniques. By contrast, clonal relationships between PCa metastases and a potentiating clone have been consistently identified (19 studies, 732 specimens). Metastatic specimens demonstrate consistent truncal genomic aberrations that suggest monoclonal metastatic progenitors. CONCLUSIONS: The relationship between the clonal dynamics of PCa and clinical outcomes needs further investigation. It is likely that this will provide a biological rationale for whether radical treatment of the primary tumour benefits patients with oligometastatic PCa. Future studies on the mutational burden in primary disease at single-cell resolution should permit the identification of clonal patterns underpinning the origin of lethal PCa. PATIENT SUMMARY: Prostate cancers arise in different parts of the prostate because of DNA mutations that occur by chance at different times. These cancer cells and their origin can be tracked by DNA mapping. In this review we summarise the state of the art and outline what further science is needed to provide the missing answers.
引用
- Erickson A, Hayes A, Rajakumar T, et al. A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. Eur Urol Oncol. 2021. PMID: 33888445. doi:10.1016/j.euo.2021.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。